Chemokine and inflammatory cytokine changes during chronic wound healing

Wound Repair and Regeneration

Volumn 5, Issue 4, 1997, Pages 310-322

  Fivenson, David P ^a,d   Faria, Duyen T ^a   Nickoloff, Brian J ^b   Poverini, Peter J ^c   Kunkel, Steven ^c   Burdick, Marie ^c   Strieter, Robert M ^c  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000363576     PISSN: 10671927     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-475X.1997.50405.x     Document Type: Article

References (32)

1. Falanga V. Chronic wounds: pathophysiologic and experimental considerations. J Invest Dermatol 1993;100:721-5.
2. Jyung RW, Mustoe TA. Role of cytokines in wound repair. In: Oppenheim J, editor. Clinical applications of cytokines. New York: Oxford Univ Press;1993.p.307-29.
3. Mauviel A, Uitto J. The extracellular matrix in wound healing: role of the cytokine network. Wounds 1993;5:137-52.
4. Li V, Barnhill R. Angiogenesis in dermatology: pathophysiology and clinical implications. Prog Derm 1995;29:1-12.
5. Margolis DJ, Cohen JH. Management of chronic venous leg ulcers: a literature guided approach. Clinics Dermatol 1994;12:19-26.
6. Davidson JM. Wound repair. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates. New York: Raven Press;1992.p.???
7. Falanga V. Growth factors and wound healing. Dermatol Clinics 1993;11:667-75.
8. Streiter RM, Kunkel SL. Chemokines and the lung. In: Crystal R, West J, Weibel E, Barnes ???, editors. The lung: scientific foundations. 2nd ed. New York: Raven Press; 1996.p.???
9. Walz A, Baggiolini M. Generation of the neutrophil-activating peptide NAP2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J Exp Med 1990;171:449-54.
10. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994;55:97-149.
11. Strieter RM, Lukacs NW, Standiford TJ, Kunkel SL. Cytokines and lung inflammation. Thorax 1993;48:765-9.
12. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Einer SG, Strieter RM. Interleukin-8 (IL-8) as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
13. Taub DD, Oppenheim JJ. Review of the chemokine meeting: the Third International Symposium of Chemotactic Cytokines. Cytokine 1993;5:175-9.
14. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe FJ. Inhibition of angiogenesis by recombinant human platelet factor-4. Science 1990;247:77-9.
15. Strieter RM, Kunkel SL, Arenberg DA, Burdick MD, Polverini PJ. Interferon γ-inducible protein 10 (IP10) a member of the CXC chemokine family is an inhibitor of angiogenesis. Biochem Biophys Res Comm 1995;210:51-7.
16. Cocchi F, deVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1α and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-5.
17. DiPietro LA, Polverini PJ. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1. Am J Pathol 1993;143:678-84.
18. Kasama T, Streiter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL. Interleukin 10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 1995;95:2868-76.
19. Kasama T, Streiter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994;152:3559-69.
20. Fahey TJ, Sherry B, Tracey KJ, van Deventer S, Jones WG, Minei JP, Morgello S, Shires GT, Cerami A. Cytokine production in a model of wound healing: the appearance of MIP-1, MIP-2, cachectin/TNF and IL-1. Cytokine 1990;2:92-9.
21. Fivenson DP, Faria DT, Nickoloff BJ, Poverini PJ, Strieter RM. Biological wound dressings function as a reservoir for C-X-C chemokines in chronic venous ulcer therapy [abstract]. Clin Res 1994;42:232.
22. Herrick SE, Sloan P, McGurk M, Freak L, McCollum CN, Ferguson MWJ. Sequential changes in the histologic pattern and extracelluar matrix deposition during healing of chronic venous ulcers. Am J Pathol 1992;141:1085-95.
23. Granstein RD, Rook A, Flotte TJ, Amento EP. A controlled trial of intralesional recombinant gamma interferon in the treatment of keloidal scarring. Arch Dermatol 1990;126:1295-8.
24. Luster AD, Leder P. IP10, a C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993;178:1057-65.
25. Gottleib AB, Luster AD, Posnett DN, Carter DM. Detection of γ-interferon-induced protein (IP-10) in psoriatic scales. J Exp Med 1988;168:941-8.
26. Uyermura K, Yamamura M, Fivenson DP, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell mediated response. J Invest Dermatol 1993;101:701-5.
27. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-61.
28. Vitale MK, Willwerth-Fortin J, Robbins K Management of children on interferon therapy. Pediatr Nurs 1993;19:230-4.
29. Hou Z, Faria DT, Strieter RM, Ladin DA, Fivenson DP. Suppressive effects of IL-10 on T-cell mitogenesis in chronic wound fluid [abstract]. J Invest Dermatol 1996;106:941.
30. Kim J, Modlin RL, Dubinett SM, McHugh T, Nickoloff BJ, Uyemura K. IL-10 production in cutaneous basal and squamous cell carcinoma: a mechanism for evading the local T cell immune response. J Immunol 1995;155:2240-7.
31. de Haan P, Sampat S, van der Raaij EM, Bruynzeel I, Boorsma DM, Willemze R, Stoof TJ. Effect of calcitriol on growth, differentiation, chemokine mRNA expression of cultured keratinocytes and on keratinocyte-T cell binding. Acta Derm Venereol Suppl (Stockh) 1994;186:52-4.
32. Hammerberg C, Arend WP, Fisher GJ, Chan LS, Berger AE, Haskill JS, Voorhees JJ, Cooper KD. Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J Clin Invest 1992;90:571-83.